In another try at lung cancer niche, J&J nabs a potential Tagrisso rival for $50M-plus
Weeks after bowing out of a billion-dollar deal with Aduro Biotech, J&J is back to the drawing board with another oncology licensing pact that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
